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ABSTRACT
Objectives: To prevent pelvic inﬂammatory disease (PID),
some experts recommend screening for sexually transmitted
infection (STI) every 12 months, with more frequent screen-
ing suggested in higher-risk women. Nevertheless, the time
from STI acquisition to PID development, possibly an impor-
tant factor to consider in screening interval choice, is
unknown and its inﬂuence on the effectiveness and cost-
effectiveness of screening is unclear.
Methods: Using a Markov model, we estimated PID cases
averted and the incremental cost-effectiveness resulting from
6- or 12-month screening strategies for high-risk young
women (6%/year infection risk, 2.8%/year PID risk with
12-month screening) while varying PID development time
from 1 to 12 months after initial infection. Lower-risk
women and alternative parameter values were examined in
sensitivity analyses.
Results: Relative to 12-month screening, 6-month screening
decreases PID cases from 6.0% (1 month development time)
to 19.4% (12 months); the incremental cost per quality-
adjusted life-year (QALY) gained compared with the other
strategies varies from $16,600 (12 months development
time) to $31,800 (1 month) for high-risk women. In lower-
risk women, every 6-month screening is more economically
unfavorable, with greater costs per QALY gained at shorter
PID development time.
Conclusion: From a cost-effectiveness standpoint, uncer-
tainty about PID development time is not a signiﬁcant factor
in choosing a screening interval in high-risk women, but
could be important in lower-risk groups. Signiﬁcant increases
in PID cases averted occur with more frequent screening
when PID development time is lengthened, which may allow
estimation of this interval through the use of more sophisti-
cated modeling techniques.
Keywords: cost-effectiveness analysis, decision analysis,
pelvic inﬂammatory disease, sexually transmitted disease.
Introduction
Pelvic inﬂammatory disease (PID), caused most fre-
quently by sexually transmitted infection (STI), is a
major cause of disability in young women, leading to
infertility, ectopic pregnancy, and chronic pelvic pain
[1]. PID occurs because of migration of pathogens
(most commonly chlamydia and gonorrhea) to the
upper female genital tract, provoking tubal inﬂamma-
tion and subsequent tissue damage [2].To prevent PID,
screening for STI is recommended, but the optimal
screening interval is unclear [3,4]. The Centers for
Disease Control and Prevention (CDC) recommends
screening sexually active adolescent women for
chlamydia “at least annually” and annual screening
for women aged 20 to 25 years [3], while the US
Preventive Services Task Force suggests every 6- to
12-month screening for previously infected women,
because of high rates of reinfection [4]. Other authors
recommend twice yearly screening for women less than
25 years old [5] with consideration for routine gonor-
rhea screening in high-risk young women [6].
The costs and beneﬁts of STI screening may be
inﬂuenced by a variety of infection characteristics.
Many women develop infections and carry them
(asymptomatically or symptomatically) for prolonged
periods of time [3]. Because screening for STI has been
shown to be beneﬁcial for the individual infected
woman in preventing PID [4,7], there must be some
time interval between initial infection and PID develop-
ment; otherwise screening would not be useful for the
infected woman if PID immediately followed infection.
Many previous cost-effectiveness models have not spe-
ciﬁcally addressed development time [8–11], while
another assumes progression to PIDwithin 6 months of
infection [12]. Mechanisms for PID development in
infected women are unclear, with the prolonged nature
of untreated infections and reinfection rates both likely
contributing to the onset of PID, among other factors
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[2,13,14]. Screening-initiated treatment of STI could
thus prevent PID in the infected woman by interrupting
the damaging effects of: (1) persistent infection; (2)
subsequent infections or reinfections in women with
untreated or belatedly treated prior infections; or (3) the
combination of STI and concurrent non-sexually trans-
mitted vaginal infection [15]. The time interval between
STI and PID development may be a function of all these
factors, among others. Whatever the mechanism, the
PID development time remains unmeasured, but could
be an important factor to consider in choosing STI
screening intervals. For example, if the PID develop-
ment time is relatively short, screening at shorter inter-
vals could be more favorable than at longer intervals.
On the other hand, if a long delay between STI acqui-
sition and PIDdevelopment exists, then screeningmight
be needed less often. Measurement of this interval is
complicated by the frequency of asymptomatic infec-
tions and of asymptomatic PID, the role of mixed
infections in the etiology of PID, as well as the possible
inﬂuences of the menstrual cycle and of behaviors, such
as douching [13,15–24].
There is a tension between the level of biological
realism incorporated into a model and the model’s
complexity and data requirements. Since the time
between infection and PID development may be an
important factor in screening interval choice but has
been difﬁcult to measure, its effect may be estimated
through mathematical modeling. In this analysis, we
examine how variation of PID development time
changes the effectiveness and cost-effectiveness of 6-
and 12-month screening intervals, seeking to under-
stand the importance of measuring PID development
time and including it in models of PID.
Methods
We constructed a Markov decision model for the
natural history of PID, with the ability to vary PID
development time. Using this model, we estimated the
proportion of PID cases prevented and the incremental
cost per quality-adjusted life-year (QALY) gained by
combined chlamydia and gonorrhea screening, com-
paring three strategies: no screening, every 6-month
screening, and every 12-month screening, while exam-
ining the impact of varying PID development time
from 1 to 12 months. Our baseline analysis examined
high-risk young women, the focus of present STI
screening programs, over a 4-year time horizon. The
analysis follows the reference case recommendations
of the Panel on Cost-Effectiveness in Health and Medi-
cine, taking a societal perspective and discounting
future costs and beneﬁts at 3% per year [25].
We made several simplifying assumptions in our
model. Chlamydial and gonococcal etiologies for PID
were considered together, rather than separately, thus
assuming that acute infection for either is the same and
PID development time was similar for each. Because
of both the theoretical nature of the model and the lack
of reliable data,we also considered all possible causes of
progression (i.e., prolonged infection, subsequent in-
fection or reinfection, or concurrent non-STI) from in-
fection to PID together, modeling the likelihood of
progression based on the GYN Infections Follow-
Through (GIFT) Study, a prospective cohort study that
followed adolescents and youngwomen at STI high risk
over an average of 4 years [15,23]. Based on the GIFT
Study, we used a 4-year time horizon in our base-case
analysis, but considered longer time horizons in sensi-
tivity analyses. We assumed no deaths from acute PID
or its complications, slightly biasing the model against
screening.Wemodeled all PID complications as a single
state, and assumed that PID complications were not
cured over the model time horizon. As in the GIFT
Study, we deﬁne high-risk women, using a risk stratiﬁ-
cation paradigm [26], as those with a score 3, where
aged 24 years or more = 1, black race = 2, never preg-
nant = 1, two or more sexual partners = 1, douches at
least once a month = 1, and any prior STI = 2.
Figure 1 is a schematic representation of the model.
The Markov cycle length was 1 month. Hypothetical
cohorts of 18-year-old women began in the well state.
Based on infection risks and the likelihood of symp-
tomatic infection, they could transition to the asymp-
tomatic or symptomatic infection state. Asymptomatic
infections could become symptomatic over time.
Infected women transitioned to PID based on the time
varying monthly risk of progression to PID. Similar to
infection, PID was modeled as symptomatic or asymp-
tomatic, with the possibility of asymptomatic PID
becoming symptomatic (estimated at 1% per month,
varied from 0 to 10% in sensitivity analyses). PID of
either type carried the same risk of complications.
Women could recover from infection or from PID
because of treatment after screening or after presenta-
tion with symptomatic illness. As reported in the lit-
erature, infections could also resolve spontaneously
[27,28]; we assumed identical spontaneous resolution
rates for chlamydia and gonorrhea, possibly biasing
against screening. Women were subject to reinfection
and rescreening once treated or spontaneously cured.
Women in all health states faced a small risk of death
from other causes, based on the US life tables [29].
Probabilities, costs, and utilities used in our model
are shown in Table 1. In our model, 21.9% of our
population of high-risk women became infected over
4 years (6.0% per year) in the baseline analysis
[5,6,12,23,30]. Thirty percent of infections were
symptomatic and 70% of symptomatic infections were
treated adequately. Of the women with uncured symp-
tomatic infections, 30% developed PID in the ﬁrst
month after infection [9]. In all other infected women,
the interval between infection and PID development
was varied, with the model calibrated so that a 10.9%
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PID risk was observed over 4 years (2.8% per year)
when a 12-month screening interval was in place, as
was seen in the GIFT Study [15,23], which is consis-
tent with rates seen in other populations of high-
risk young women [7,22,31]. In sensitivity analyses,
we also examined scenarios where symptomatically
infected women had the same PID development inter-
vals as the remainder of the population, where women
were followed over a 10-year time horizon, and where
screening was begun on 15-year-olds (rather than
18-year-olds). Women with PID had a 25% risk of
chronic complications [1,32,33]. Screening and treat-
ment costs included ofﬁce visits costing $40 each [34],
one for screening and a second for treatment, testing
costs (DNA ampliﬁcation assay for N. gonorrhoeae
and C. trachomatis, baseline $25, range $10–40
[10,12]), and medication costs. Also included were the
indirect costs of seeking or receiving care (2 hours for
each ofﬁce visit), based on the US hourly wage rates
for non-farm workers [35]. A 5% risk of requiring
care for medication side effects, costing $49 [12], was
also included in infection treatment costs. Women
who screened positive for chlamydia were treated
for chlamydia with azithromycin, costing $28; those
screening positive for gonorrhea were treated for both
gonococcus and chlamydia with azithromycin and
ciproﬂoxacin, costing a total of $34 [36]. Symptomatic
infections of either type were treated with ceftriaxone
125 mg intramuscularly and azithromycin, costing
$42 [36]. Baseline costs for screening and infection
treatment were set relatively high to bias against more
frequent screening. The cost of treating symptomatic
PID was varied widely in sensitivity analyses based on
several cost data sources [9,12,37–39] and a variety of
inpatient versus outpatient treatment scenarios. The
base-case value for PID treatment costs, including the
cost of complications, was the discounted average life-
time cost of PID calculated by Yeh et al. [38] inﬂated to
2004 US dollars using the Consumer Price Index [40].
Utilities were obtained from the literature [41,42].
Screening for chlamydia and gonorrhea was sensitive
and very speciﬁc [14].
In the baseline analysis, we represented intervals
between asymptomatic infection and PID development
as normal distributions centered on a mean, which
ranged from 1 to 12 months based on mean chlamydia
duration estimates of approximately 1 year in un-
treated women [12,27]: the distributions for develop-
ment time of 3, 6, and 9 months are shown in
Figure 2a. These distributions represent the time
varying risk of progression from infection to PID for
each development time considered. Similar distribu-
tions were used for other development time from 1 to
12 months in our baseline analysis, but are not shown.
Distributions were then scaled to produce a 10.9%
risk of PID [15,23] over 4 years when a 12-month
screening program was in place (Fig. 2b). We exam-
ined all parameters in one-way sensitivity analyses,
and selected parameters in multiway sensitivity analy-
ses. In addition, we examined alternative screening
strategies and model assumptions in structural sensi-
tivity analyses.
Results
In the baseline analysis, more PID cases are avoided
with more frequent screening when PID development
time is longer, as is expected. If PID develops on
average in 1 month, the relative decrease in PID cases
is 6.0% for 6-month compared with 12-month screen-
ing, increasing to 19.4% when PID development time
is 12 months. Nevertheless, cost-effectiveness analysis
results are less sensitive to variation of PID develop-
ment time in our base-case analysis of high-risk
women, as summarized in Figure 3. The incremental
cost-effectiveness ratio for 6-month screening com-
pared with no screening is $31,800 per QALY gained
when the mean time to PID is 1 month (0.014 QALY’s
Asymptomatic
Infection
Symptomatic
Infection
Asymptomatic
PID
COMPLICATION
(Infertility, ectopic,
chronic pain)
RECOVERED
WELL
Symptomatic
PID
Figure 1 The Markov model. The Markov cycle length is 1 month. PID,
pelvic inﬂammatory disease.
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gained at a cost of $444) and decreases to $16,600 per
QALY gained when the mean time to PID is 12 months
(0.022 QALY’s gained, costing $370). Compared with
6-month screening, screening at 12-month intervals
in high-risk patients has larger incremental cost-
effectiveness ratios and is less effective through all PID
development time, thus removing it from consider-
ation for these patients because of extended domi-
nance [43].
We examined many other possible PID risk distri-
butions in sensitivity analyses, including uniform,
declining exponential, declining linear, normal with
broader or narrower widths, and square wave distri-
butions. Cost-effectiveness results using these other
distributions showed similar relative insensitivity to
variation of PID development time. Considering
10-year time horizons and beginning screening in high-
risk groups at age 15 decreased cost-effectiveness
ratios, further favoring screening interventions. Age in
itself had minimal effects; longer time horizons were
most inﬂuential on results.
Results were most sensitive to variation of infection
rate (Fig. 4). For each infection rate, the curves show
the range of values seen as mean PID development time
is varied from 1 to 12 months. As the yearly infection
risk decreased below 5%, the range of values increased
and became more economically unfavorable with
greater absolute differences seen over the range of
PID development time. When the yearly infection risk
was 2.5%, the cost per QALY gained for 6-month
screening was greater than $40,000 through the entire
range of PID onset times, varying from $43,000
(12 months) to $72,700 (1 month). With infection risk
at this lower level, 12-month screening had a cost per
QALY gained $300–500 less than 6-month screening.
Varying most other variables in one-way sensitivity
analyses had little impact on the magnitude or range of
incremental cost-effectiveness ratios seen when PID
development time was varied in high-risk women.
For example, decreasing screening sensitivity to 65%
increased incremental cost-effectiveness ratios by 33%
to 40%: $23,300 per QALY if PID development
time was 12 months or $42,400 per QALY if it
was 1 month. Nevertheless, decreased screening costs
had signiﬁcant impact on results, decreasing cost-
effectiveness ratios by more than half if screening costs
were $40 or less. When screening sensitivity, screening
cost, and yearly infection risk are varied in probabilis-
tic sensitivity analyses over the ranges listed in Table 1
using triangular distributions, 6-month screening is
strongly preferred; if societal willingness to pay is
$50,000 per QALY gained, 6-month screening is pre-
ferred in 96.5% of model iterations if PID develop-
ment time is 1 month and 100% of the time if
development time is 6 or 12 months.
In sensitivity analyses, heterogeneity in PID devel-
opment was examined in two ways. First, if yearly PID
development risk is decreased to 1% (compared with
2.8% per year, or 10.9% over 4 years, in the base
case), cost-effectiveness ratios increased by a factor
Table 1 Parameter values used in the baseline analysis and ranges examined in sensitivity analyses
Parameter Baseline value Range Reference
Infection
Likelihood (%/year) 6.0 2.5–15 5,6,12,23,30
% Symptomatic 30 0–50 3,41,44
% Treated 70 0–100 16,17,30,41,45,46
Treatment effectiveness (%) 96 94–100 12,47
Spontaneous cure (%/year) 54 40–70 27,28,32
Gonorrhea relative likelihood (%) 19 5–30 32
PID
Likelihood (%/year) 2.8 1–5 15,16,23,24
% Symptomatic 40 0–100 13,22
% Treated 70 50–100 16,17,45
Treatment effectiveness (%) 60 40–80 24,48
% PID complication 25 10–40 1,33
Screening (%)
Sensitivity 90 65–96 14
Speciﬁcity 99 99–100 14
Screening adherence 60 30–90 49
Treatment adherence 60 30–90 9,50
Costs ($)
Screening 81 20–100 9,10,12,14,34,35
Infection treatment 87 35–100 9,10,12,34–36
PID treatment 2359 269–5000 9,12,37–39
Indirect (per hour) 16 0–40 35
Utility
Infection (symptomatic) 0.9 0.8–0.99 41,42
PID (symptomatic) 0.65 0.5–0.8 41,42
Complication 0.6 0.4–0.8 41,42
PID, pelvic inﬂammatory disease.
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of about 2.4 ($40,000–76,300 per QALY gained)
throughout the range of PID development intervals.
Second, if the baseline assumption of immediate PID
risk in uncured symptomatically infected women is
relaxed, with these women therefore developing PID at
the same time intervals as the remainder of the infected
population, cost-effectiveness ratios decrease by less
than $1000 when calculated using either base-case or
sensitivity analysis infection incidence rates.
Alternative model assumptions also had little inﬂu-
ence on the effect that PID development time variation
has on screening cost-effectiveness. If women were
rescreened 3 to 4 months after infection as recom-
mended for chlamydia infection by the CDC (3), then
resumed 6-month screening after a negative screen,
cost-effectiveness ratios decreased less than $1000 from
baseline. Similarly, increasing STI risk after previous
infection (to a 15% reinfection rate over 3 months) or
increasing PID and complication risks after prior PID
episodes (to a 25% greater relative risk than baseline
values) had little inﬂuence on results compared with
those found using base-case assumptions.
Discussion
In high-risk women, we found that the time from
initial infection to the development of PID was a
relatively minor factor in determining the cost-
effectiveness of a 6-month combined chlamydia and
gonorrhea screening strategy compared with a 12-
month strategy. Nevertheless, the risk of infection,
regardless of PID development time, was the most
signiﬁcant factor in changing cost-effectiveness results,
with 6-month screening favored in high-risk women
but becoming more unfavorable in lower-risk women,
because of smaller gains in effectiveness being out-
weighed by higher costs from more frequent screening.
Also, as infection or PID risks decreased, PID develop-
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Figure 2 Risk distributions. (a) Truncated
normal distributions for risk of progression
from infection to pelvic inﬂammatory disease
(PID). Similar distributions were used for other
development time from 1 to 12 months, but are
not shown. (b) Distributions were scaled to
produce a 2.8%/year (or 10.9%/4 years) risk of
progression from infection to PID when a
12-month screening program is in place, repro-
ducing clinical trial results [15,23]. Distribution
heights are smaller for shorter development
time because of the effect of shorter develop-
ment time causing more PID cases earlier in the
4-year time frame of the model.
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ment time became more important, with shorter devel-
opment time making more frequent screening less
economically favorable. Nevertheless, we found the
magnitude of the interval between infection and PID
development to be a signiﬁcant factor when PID cases
prevented are considered.
Given the inherent difﬁculties in measuring PID
development time and the multifactorial complexity of
its components, should there be further efforts to
measure it? From an economic standpoint, the costs of
obtaining better information would not be worthwhile
when considering screening strategy choices in high-
risk groups, given the relative insensitivity of the incre-
mental cost-effectiveness ratio to variation of PID
development time; the tension between biological
plausibility and model complexity would seem to favor
a simpler model in this patient group. For lower-risk
populations, further attempts at measurement of PID
development time might be reasonable based on abso-
lute differences in cost-effectiveness ratios over the
range of intervals studied. Nevertheless, given that, at
best, costs per QALY are $43,000 or more for 6-month
combined chlamydia and gonorrhea screening when
the yearly infection risk is 2.5% or less, alternative
screening strategies (screening for chlamydia only, less
frequent screening, and/or further attempts at deﬁning
higher-risk subgroups) would be worth considering
ﬁrst in lower-risk groups. Further supporting this
proposition is the difﬁculty inherent in attempting to
disentangle the multiple factors and uncertainties sur-
rounding the pathophysiology and epidemiology of
PID. Nevertheless, modeling may allow estimation of
PID development time if differences in PID rates
between screening programs are available and the PID
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Figure 3 Results—cost-effectiveness. The
incremental cost-effectiveness of 6-month
screening compared with no screening as pelvic
inﬂammatory disease (PID) development time
varies from 1 to 12 months and all other param-
eters at baseline values as shown in Table 1.
QALY, quality-adjusted life-year.
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Figure 4 Sensitivity analysis––infection risk.
Incremental cost-effectiveness ratio of 6-month
screening with variation of pelvic inﬂammatory
disease (PID) development time from 1 to
12 months (curves) and of yearly infection risks
(x-axis). QALY, quality-adjusted life-year.
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model can account for the many factors inﬂuencing
PID development, including the PID risks of etiologic
infections, the inﬂuence of recurrent infections, and the
effects of age, race, sexual and other factors, and popu-
lation infection prevalence.
Previous models have examined the cost-
effectiveness of screening for chlamydia alone, ﬁnding
this intervention cost-saving in high-risk young women
[7,11] and costing less than $25,000 in lower-risk
women less than 30 years old [12]. Our results tend
toward higher costs, since we also include screening
and treatment for gonorrhea, a less common infection,
in our analysis and set high baseline costs for screening
and treatment to bias the model against more frequent
screening.
Our analysis has limitations. We did not model all
possible infectious agents responsible for PID (e.g.,
anaerobes, Gardnerella vaginalis, Haemophilus inﬂu-
enzae, enteric Gram negative rods, Streptococcus aga-
lactiae, cytomegalovirus, Mycoplasma hominis, and
Ureaplasma urealyticum) separately. As a result, we did
not account for etiologies other than chlamydia and
gonorrhea in our model [13,22,24], perhaps overesti-
mating the effects of screening.Nevertheless, decreasing
screening sensitivity, one way of accounting for other
infections, has little effect on cost-effectiveness results.
Considering all infectious agents together in our theo-
retical model assumes similar infection characteristics,
development time, and tendencies toward progression
and complications, but not capturing the heterogeneity
of the various etiologic agents. We did not consider the
possible harms of more frequent screening: adverse
effects of false positive screening on patients and part-
ners, the inconvenience of obtaining test specimens, and
the potential hazards of more frequent exposure to
antibiotics. Finally, we used a static cohort model, not a
dynamic population disease transmission model [8,11].
Our model was developed to test the importance of PID
development time, an unmeasured and perhaps unmea-
surable variable, and is a preliminary step in the devel-
opment of a comprehensive model, which will consider
dynamic population forces in STI incidence, prevalence,
and spread, as well as other factors surrounding PID
prevention and management. In this analysis, we found
that screening high-risk youngwomen for both chlamy-
dia and gonorrhea every 6 months is economically rea-
sonable and strongly favored over 12-month screening,
but these results should be considered preliminary,
based on the underlying motivation and limitations of
our present model. Finally, the base-case analysis
assumes homogeneity of women’s responses to STI. It is
possible that modeling a more complex population,
with some subgroups developing PID relatively earlier
than others, would alter results.
We conclude that, from a cost-effectiveness stand-
point, time from infection onset to PID development is
not a signiﬁcant factor in screening interval choice for
high-risk women. Nevertheless, PID development time
could be important to consider in lower-risk groups. It
appears that PID cost-effectiveness models for women
at high STI risk may safely omit PID development time
without signiﬁcantly affecting results but, given its
effect on PID cases prevented, more sophisticated mod-
eling may be useful to estimate PID development time
when changes in PID risk resulting from different
screening intervals are known.
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